- Home
- GHY vs CSTL Comparison
GHY vs CSTL Comparison
Compare GHY & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHY
- CSTL
- Stock Information
- Founded
- GHY 2012
- CSTL 2007
- Country
- GHY United States
- CSTL United States
- Employees
- GHY N/A
- CSTL N/A
- Industry
- GHY Trusts Except Educational Religious and Charitable
- CSTL Medical Specialities
- Sector
- GHY Finance
- CSTL Health Care
- Exchange
- GHY Nasdaq
- CSTL Nasdaq
- Market Cap
- GHY 548.8M
- CSTL 456.2M
- IPO Year
- GHY N/A
- CSTL 2019
- Fundamental
- Price
- GHY $13.54
- CSTL $19.66
- Analyst Decision
- GHY
- CSTL Strong Buy
- Analyst Count
- GHY 0
- CSTL 6
- Target Price
- GHY N/A
- CSTL $37.67
- AVG Volume (30 Days)
- GHY 184.8K
- CSTL 442.5K
- Earning Date
- GHY 01-01-0001
- CSTL 08-04-2025
- Dividend Yield
- GHY 10.58%
- CSTL N/A
- EPS Growth
- GHY N/A
- CSTL N/A
- EPS
- GHY N/A
- CSTL N/A
- Revenue
- GHY N/A
- CSTL $347,083,000.00
- Revenue This Year
- GHY N/A
- CSTL N/A
- Revenue Next Year
- GHY N/A
- CSTL $1.36
- P/E Ratio
- GHY N/A
- CSTL N/A
- Revenue Growth
- GHY N/A
- CSTL 38.43
- 52 Week Low
- GHY $10.24
- CSTL $15.45
- 52 Week High
- GHY $11.92
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- GHY 59.61
- CSTL 55.46
- Support Level
- GHY $13.58
- CSTL $19.21
- Resistance Level
- GHY $13.74
- CSTL $20.26
- Average True Range (ATR)
- GHY 0.10
- CSTL 0.64
- MACD
- GHY 0.00
- CSTL -0.05
- Stochastic Oscillator
- GHY 68.25
- CSTL 60.34
About GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.